Logo-jcvtr

Submitted: 30 Jul 2025
Revision: 10 Oct 2025
Accepted: 29 Nov 2025
ePublished: 30 Mar 2026
EndNote EndNote

(Enw Format - Win & Mac)

BibTeX BibTeX

(Bib Format - Win & Mac)

Bookends Bookends

(Ris Format - Mac only)

EasyBib EasyBib

(Ris Format - Win & Mac)

Medlars Medlars

(Txt Format - Win & Mac)

Mendeley Web Mendeley Web
Mendeley Mendeley

(Ris Format - Win & Mac)

Papers Papers

(Ris Format - Win & Mac)

ProCite ProCite

(Ris Format - Win & Mac)

Reference Manager Reference Manager

(Ris Format - Win only)

Refworks Refworks

(Refworks Format - Win & Mac)

Zotero Zotero

(Ris Format - Firefox Plugin)

J Cardiovasc Thorac Res. 2026;18(1): 46-54.
doi: 10.34172/jcvtr.026.33666
  Abstract View: 87
  PDF Download: 64

Original Article

Exploring cardiovascular risk in subclinical hypothyroidism: The impact of TSHR gene expression and systemic biomarkers

Manjusha Kottola 1 ORCID logo, Desigamani Kanniyappan 2* ORCID logo, Damodaran Boopathi 3, Jeyapal Vidhyadharan 4, Vishnu Manjerikattil Govindan 1, Vineetha Vijayan 1, Joby Paruthiparayil Jose 1, Jisha Anjali Madhavan Pillai 1, Rajitha Puthiya Purayil 1, Swathi Thoduvayil 1, Midhun Thazhissery Mohanan 1, Dinesh Roy Divakaran 5* ORCID logo

1 Meenakshi Academy of Higher Education and Research (MAHER- Deemed to be University), Chennai, India
2 Department of Biochemistry, Madha Medical College and Hospital, Kovur, Chennai, India
3 Department of Psychology, Meenakshi Academy of Higher Education and Research (MAHER- Deemed to be University), Chennai, India
4 Hridayala Heart and Robotic Research Centre Pvt Ltd, Thiruvananthapuram, India
5 Genetika, Centre for Advanced Genetic Studies, Thiruvananthapuram, India
*Corresponding Authors: Desigamani Kanniyappan, Email: [email protected]; Dinesh Roy Divakaran, Email: [email protected]

Abstract

Introduction: Subclinical hypothyroidism (SCH), defined by elevated thyroid-stimulating hormone (TSH) with normal thyroid hormone levels, affects approximately 3–8% of the population. Growing evidence indicates that thyroid-stimulating hormone receptor (TSHR) expression in cardiovascular tissues, together with systemic inflammation (IL-6) and oxidative stress (3-nitrotyrosine), may contribute to cardiovascular dysfunction in SCH. This study aimed to evaluate the association between TSHR gene expression and systemic biomarkers—hormonal, inflammatory, and oxidative—and to assess their predictive value for cardiovascular risk in SCH patients.

Methods: A case–control design was adopted involving 150 SCH subjects and 150 age- and sex-matched healthy controls. Demographic and clinical data were collected using structured interviews. Fasting blood samples were analyzed for TSH (CLIA), IL-6, and 3-nitrotyrosine (ELISA), while TSHR gene expression was quantified using real-time PCR with GAPDH as an internal control. Statistical analyses were performed using Stata version 17.0.

Results: Compared with controls, SCH patients showed significantly higher levels of TSH, IL-6, 3-nitrotyrosine, and TSHR gene expression (P<0.05). Receiver operating characteristic (ROC) analysis revealed high diagnostic accuracy for these parameters. Although univariate analysis associated TSHR dysregulation with SCH, multivariate regression identified TSH as the only independent predictor of disease status. Oxidative stress demonstrated a significant positive association with TSHR expression, whereas IL-6 showed no independent influence.

Conclusion: SCH is characterized by elevated hormonal, oxidative, and inflammatory markers, with oxidative stress contributing to TSHR upregulation. TSH remains the strongest independent predictor, underscoring the hormonal–oxidative interaction in cardiovascular risk among SCH patients.


First Name
Last Name
Email Address
Comments
Security code


Abstract View: 88

Your browser does not support the canvas element.

PDF Download: 64

Your browser does not support the canvas element.